Du Qin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Du Qin has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Corinne Louche‐Pélissier
Centre de Recherche en Nutrition Humaine Rhône‐Alpes, F‐69310 Pierre Bénite, France
1 shared publicationFang Wang
Department of Oncology, Affiliated Hospital of Jining Medical College, Jining 272029, China,
1 shared publicationJunye Wang
Department of Oncology, Affiliated Hospital of Jining Medical College, Jining 272029, China,
1 shared publicationLaure Gabert
Centre de Recherche en Nutrition Humaine Rhône‐Alpes, F‐69310 Pierre Bénite, France
1 shared publicationLei Han
Department of Oncology, Affiliated Hospital of Jining Medical College, Jining 272029, China,
1 shared publication- Martine Laville
Rhône-Alpes Research Center for Human Nutrition, Université-Lyon, CarMeN Laboratory, Hospices Civils de Lyon, Lyon, France
1 shared publication
Latest Publications
- Open Access
- 1 October 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 6383-6394
LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer
Background: Increasing evidence has shown that long non-coding RNAs (lncRNAs) play important roles in the occurrence and development of human cancers. LINC00460, a novel tumor-related lncRNA, has been reported to be involved in several types of human malignancies. However, the role of LINC00460 in gastric cancer (GC) is still unclear. The present study aimed at exploring the biological role of LINC00460 in GC and illuminating the potential molecular mechanisms. Methods: In this study, qRT-PCR, western blotting, MTT assay, and Transwell invasion assay were used to conduct relevant experimental analysis. Results: Here, we found that LINC00460 was highly expressed in GC tissues and cell lines. Moreover, LINC00460 over-expression was found to promote GC cell proliferation, migration and invasion, whereas LINC00460 down-regulation significantly inhibited these processes. Notably, we confirmed that LINC00460 could up-regulate KDM2A expression by competitively binding to miR-342-3p in GC cells. Furthermore, the suppressive effects of LINC00460 down-regulation on GC cell proliferation, migration and invasion were partially reversed by a miR-342-3p inhibitor. Conclusion: In summary, our findings provide evidence for LINC00460 as a potential therapeutic target in GC.
- 1 October 2018
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 6383-6394
Open AccessLINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer
Background: Increasing evidence has shown that long non-coding RNAs (lncRNAs) play important roles in the occurrence and development of human cancers. LINC00460, a novel tumor-related lncRNA, has been reported to be involved in several types of human malignancies. However, the role of LINC00460 in gastric cancer (GC) is still unclear. The present study aimed at exploring the biological role of LINC00460 in GC and illuminating the potential molecular mechanisms. Methods: In this study, qRT-PCR, western blotting, MTT assay, and Transwell invasion assay were used to conduct relevant experimental analysis. Results: Here, we found that LINC00460 was highly expressed in GC tissues and cell lines. Moreover, LINC00460 over-expression was found to promote GC cell proliferation, migration and invasion, whereas LINC00460 down-regulation significantly inhibited these processes. Notably, we confirmed that LINC00460 could up-regulate KDM2A expression by competitively binding to miR-342-3p in GC cells. Furthermore, the suppressive effects of LINC00460 down-regulation on GC cell proliferation, migration and invasion were partially reversed by a miR-342-3p inhibitor. Conclusion: In summary, our findings provide evidence for LINC00460 as a potential therapeutic target in GC.
- 10 November 2009
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 23 (23) , 3855-3867
Validation of pentaacetylaldononitrile derivative for dual 2 H gas chromatography/mass spectrometry and 13 C gas chromatography/combustion/isotope ratio mass spectrometry analysis of glucose
A reference method to accurately define kinetics in response to the ingestion of glucose in terms of total, exogenous and endogenous glucose is to use stable‐isotope‐labelled compounds such as 2 H and 13 C glucose followed by gas chromatography/mass spectrometry (GC/MS) and gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS) analysis. The use of the usual pentaacetyl (5Ac) derivative generates difficulties in obtaining accurate and reproducible results due to the two chromatographic peaks for the syn and anti isomers, and to the isotopic effect occurring during acetylation. Therefore, the pentaacetylaldononitrile derivative (Aldo) was validated for both isotopes, and compared with the 5Ac derivative. A correction factor including carbon atom dilution (stoichiometric equation) and the kinetic isotopic effect (KIE) was determined. Analytical validation results for the 2 H GC/MS and 13 C GC/C/IRMS measurements produced acceptable results with both derivatives. When 2 H enrichments of plasma samples were ≤1 mol % excess (MPE), the repeatability (RSD Aldo Intra assay and Intra day 5Ac Intra assay and Intra day p < 0.05). When the glucose kinetics were assessed in nine human subjects, after glucose ingestion, the plasma glucose 2 H enrichments were identical with both derivatives, whereas the 13 C enrichments needed a correction factor to fit together. Due to KIE variation, this correction factor was not constant and had to be calculated for each batch of analyses, to obtain satisfactory results. Mean quantities of exogenous glucose exhibit marked difference (20.9 ± 1.3g (5Ac) vs. 26.7 ± 2.5g (Aldo)) when calculated with stoichiometric correction, but fit perfectly when calculated after application of the correction factor (22.1 ± 1.3g (5Ac) vs. 22.9 ± 1.9g (Aldo)). Finally, the pentaacetylaldononitrile derivative, used here in GC/C/IRMS for the first time, enables measurement of 2 H and 13 C enrichments in plasma glucose with a single sample preparation. Copyright © 2009 John Wiley & Sons, Ltd.
- 10 November 2009
- Published by Wiley in Rapid Communications in Mass Spectrometry
- Vol. 23 (23) , 3855-3867
Validation of pentaacetylaldononitrile derivative for dual 2 H gas chromatography/mass spectrometry and 13 C gas chromatography/combustion/isotope ratio mass spectrometry analysis of glucose
A reference method to accurately define kinetics in response to the ingestion of glucose in terms of total, exogenous and endogenous glucose is to use stable‐isotope‐labelled compounds such as 2 H and 13 C glucose followed by gas chromatography/mass spectrometry (GC/MS) and gas chromatography/combustion/isotope ratio mass spectrometry (GC/C/IRMS) analysis. The use of the usual pentaacetyl (5Ac) derivative generates difficulties in obtaining accurate and reproducible results due to the two chromatographic peaks for the syn and anti isomers, and to the isotopic effect occurring during acetylation. Therefore, the pentaacetylaldononitrile derivative (Aldo) was validated for both isotopes, and compared with the 5Ac derivative. A correction factor including carbon atom dilution (stoichiometric equation) and the kinetic isotopic effect (KIE) was determined. Analytical validation results for the 2 H GC/MS and 13 C GC/C/IRMS measurements produced acceptable results with both derivatives. When 2 H enrichments of plasma samples were ≤1 mol % excess (MPE), the repeatability (RSD Aldo Intra assay and Intra day 5Ac Intra assay and Intra day p < 0.05). When the glucose kinetics were assessed in nine human subjects, after glucose ingestion, the plasma glucose 2 H enrichments were identical with both derivatives, whereas the 13 C enrichments needed a correction factor to fit together. Due to KIE variation, this correction factor was not constant and had to be calculated for each batch of analyses, to obtain satisfactory results. Mean quantities of exogenous glucose exhibit marked difference (20.9 ± 1.3g (5Ac) vs. 26.7 ± 2.5g (Aldo)) when calculated with stoichiometric correction, but fit perfectly when calculated after application of the correction factor (22.1 ± 1.3g (5Ac) vs. 22.9 ± 1.9g (Aldo)). Finally, the pentaacetylaldononitrile derivative, used here in GC/C/IRMS for the first time, enables measurement of 2 H and 13 C enrichments in plasma glucose with a single sample preparation. Copyright © 2009 John Wiley & Sons, Ltd.